Subsequent Events |
9 Months Ended |
---|---|
Sep. 30, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events |
9. Subsequent Events
The Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC. Other than those matters described below, there were no material subsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.
On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (NKI), one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations. The Company has agreed to fund the study and provide a sufficient supply of LB-100 to conduct the study. The study is expected to take approximately two years to conduct.
On November 8, 2021, the Company granted BioPharmaWorks a fully-vested stock option (issued in the form of a warrant) to acquire shares of the Company’s common stock, exercisable for a period of from the grant date at $2.06 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The fair value of the stock option will be calculated pursuant to the Black-Scholes option-pricing model and will be charged to operations upon issuance. |